循环肿瘤DNA在乳腺癌管理中的新兴作用
The Emerging Role of Circulating Tumor DNA in the Management of Breast Cancer.
作者信息
Shoukry Mira, Broccard Sacha, Kaplan Jamie, Gabriel Emmanuel
机构信息
Department of Surgery, Section of Surgical Oncology, Mayo Clinic, Jacksonville, FL 32224, USA.
出版信息
Cancers (Basel). 2021 Jul 29;13(15):3813. doi: 10.3390/cancers13153813.
Abstract
With the incidence of breast cancer steadily rising, it is important to explore novel technologies that can allow for earlier detection of disease as well more a personalized and effective treatment approach. The concept of "liquid biopsies" and the data they provide have been increasingly studied in the recent decades. More specifically, circulating tumor DNA (ctDNA) has emerged as a potential biomarker for various cancers, including breast cancer. While methods such as mammography and tissue biopsies are the current standards for the detection and surveillance of breast cancer, ctDNA analysis has shown some promise. This review discusses the versatility of ctDNA by exploring its multiple emerging uses for the management of breast cancer. Its efficacy is also compared to current biomarkers and technologies.
摘要
随着乳腺癌发病率稳步上升，探索能够实现疾病早期检测以及更个性化和有效治疗方法的新技术至关重要。近几十年来，“液体活检”的概念及其提供的数据得到了越来越多的研究。更具体地说，循环肿瘤DNA（ctDNA）已成为包括乳腺癌在内的各种癌症的潜在生物标志物。虽然乳房X线摄影和组织活检等方法是目前乳腺癌检测和监测的标准，但ctDNA分析已显示出一些前景。本综述通过探讨ctDNA在乳腺癌管理中的多种新兴用途，讨论了其多功能性。还将其疗效与当前的生物标志物和技术进行了比较。
相似文献
1
The Emerging Role of Circulating Tumor DNA in the Management of Breast Cancer.循环肿瘤DNA在乳腺癌管理中的新兴作用
Cancers (Basel). 2021 Jul 29;13(15):3813. doi: 10.3390/cancers13153813.
2
Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications.早期乳腺癌循环肿瘤 DNA：新方向和潜在的临床应用。
Clin Adv Hematol Oncol. 2021 Mar;19(3):155-161.
3
Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.循环肿瘤 DNA（ctDNA）在非小细胞肺癌中的作用研究。
Int J Mol Sci. 2022 Aug 12;23(16):9006. doi: 10.3390/ijms23169006.
4
Circulating tumor DNA for breast cancer: Review of active clinical trials.循环肿瘤 DNA 用于乳腺癌：临床研究进展综述。
Cancer Treat Res Commun. 2022;32:100609. doi: 10.1016/j.ctarc.2022.100609. Epub 2022 Jul 12.
5
Circulating tumor DNA - Current state of play and future perspectives.循环肿瘤 DNA——现状与未来展望。
Pharmacol Res. 2018 Oct;136:35-44. doi: 10.1016/j.phrs.2018.08.017. Epub 2018 Aug 22.
6
Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers.循环肿瘤 DNA：胃肠道癌症的新兴工具。
Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-20. doi: 10.1200/EDBK_349143.
7
Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.个性化循环肿瘤DNA生物标志物可动态预测妇科癌症的治疗反应和生存情况。
PLoS One. 2015 Dec 30;10(12):e0145754. doi: 10.1371/journal.pone.0145754. eCollection 2015.
8
Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy.乳腺癌中的免疫疗法及液体活检的潜在作用
Front Oncol. 2022 Mar 15;12:802579. doi: 10.3389/fonc.2022.802579. eCollection 2022.
9
Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.循环肿瘤 DNA 作为结直肠癌根治性切除术患者（接受或不接受辅助化疗）微小残留病评估和复发风险的标志物：一项系统评价和荟萃分析。
Int J Mol Sci. 2023 Jun 16;24(12):10230. doi: 10.3390/ijms241210230.
10
The potential of ctDNA analysis in breast cancer.循环肿瘤DNA（ctDNA）分析在乳腺癌中的潜力。
Crit Rev Clin Lab Sci. 2020 Jan;57(1):54-72. doi: 10.1080/10408363.2019.1670615. Epub 2019 Nov 1.
引用本文的文献
1
Liquid Biopsy for Medical Imaging Analysis in Cancer Diagnosis.用于癌症诊断中医学影像分析的液体活检
Curr Pharm Des. 2025;31(33):2635-2650. doi: 10.2174/0113816128371883250310174153.
2
Differentiating Primary and Recurrent Lesions in Patients with a History of Breast Cancer: A Comprehensive Review.乳腺癌病史患者原发性和复发性病变的鉴别：一项综述。
Galen Med J. 2024 Apr 22;13:e3340. doi: 10.31661/gmj.v13i.3340. eCollection 2024.
3
Liquid Biopsy in the Clinical Management of Cancers.液体活检在癌症临床管理中的应用。
Int J Mol Sci. 2024 Aug 6;25(16):8594. doi: 10.3390/ijms25168594.
4
Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer.整合临床病理和分子风险预测工具以改善早期激素受体阳性/人表皮生长因子受体2阴性乳腺癌的治疗结果。
NPJ Breast Cancer. 2023 Jun 28;9(1):56. doi: 10.1038/s41523-023-00560-z.
5
Circulating Tumor Cells: From the Laboratory to the Cancer Clinic; A Closing Comment.循环肿瘤细胞：从实验室到癌症临床；结束语
Cancers (Basel). 2023 Feb 2;15(3):939. doi: 10.3390/cancers15030939.
6
Integrative analysis of multi-omics data for liquid biopsy.液体活检的多组学数据综合分析。
Br J Cancer. 2023 Feb;128(4):505-518. doi: 10.1038/s41416-022-02048-2. Epub 2022 Nov 10.
7
Database Mining Detected a Cuproptosis-Related Prognostic Signature and a Related Regulatory Axis in Breast Cancer.数据库挖掘检测到乳腺癌中的铜死亡相关预后特征和相关调控轴。
Dis Markers. 2022 Oct 19;2022:9004830. doi: 10.1155/2022/9004830. eCollection 2022.
8
Integrated Bioinformatics Analysis for the Screening of Hub Genes and Therapeutic Drugs in Androgen Receptor-Positive TNBC.雄激素受体阳性三阴性乳腺癌的枢纽基因和治疗药物的筛选的综合生物信息学分析。
Dis Markers. 2022 Sep 14;2022:4964793. doi: 10.1155/2022/4964793. eCollection 2022.
9
Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine.乳腺癌新辅助化疗反应的预测生物标志物：精准医学的现状与未来展望
Cancers (Basel). 2022 Aug 11;14(16):3876. doi: 10.3390/cancers14163876.
10
Potential utility of miRNAs for liquid biopsy in breast cancer.微小RNA在乳腺癌液体活检中的潜在应用价值
Front Oncol. 2022 Aug 4;12:940314. doi: 10.3389/fonc.2022.940314. eCollection 2022.
本文引用的文献
1
Deep-Learning-Driven Full-Waveform Inversion for Ultrasound Breast Imaging.深度学习驱动的超声乳腺成像全波形反演。
Sensors (Basel). 2021 Jul 3;21(13):4570. doi: 10.3390/s21134570.
2
Deep-LIBRA: An artificial-intelligence method for robust quantification of breast density with independent validation in breast cancer risk assessment.深量（Deep-LIBRA）：一种人工智能方法，用于稳健地量化乳腺密度，并在乳腺癌风险评估中进行独立验证。
Med Image Anal. 2021 Oct;73:102138. doi: 10.1016/j.media.2021.102138. Epub 2021 Jul 2.
3
Solid-state nanopore analysis of human genomic DNA shows unaltered global 5-hydroxymethylcytosine content associated with early-stage breast cancer.固态纳米孔分析人类基因组 DNA 显示，与早期乳腺癌相关的 5-羟甲基胞嘧啶整体含量没有改变。
Nanomedicine. 2021 Jul;35:102407. doi: 10.1016/j.nano.2021.102407. Epub 2021 Apr 24.
4
Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients.循环肿瘤 DNA 作为评估转移性乳腺癌患者对帕博西尼和氟维司群治疗反应的动态生物标志物。
Breast Cancer Res. 2021 Mar 6;23(1):31. doi: 10.1186/s13058-021-01411-0.
5
Associations of and Polymorphisms with Early-Stage Breast Cancer.[基因名称]多态性与早期乳腺癌的关联。 （你提供的原文中“and”前后缺少具体内容，请补充完整以便准确翻译）
J Clin Med. 2021 Feb 19;10(4):866. doi: 10.3390/jcm10040866.
6
Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.新辅助治疗乳腺癌患者循环肿瘤 DNA 可反映治疗应答和生存情况。
Ann Oncol. 2021 Feb;32(2):229-239. doi: 10.1016/j.annonc.2020.11.007. Epub 2020 Nov 21.
7
Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer.早期和晚期乳腺癌血浆中循环肿瘤 DNA 的超高深度靶向测序。
Cancer Sci. 2021 Jan;112(1):454-464. doi: 10.1111/cas.14697. Epub 2020 Nov 4.
8
Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.新辅助化疗后循环肿瘤 DNA 和循环肿瘤细胞与三阴性乳腺癌患者疾病复发的关系：BRE12-158 随机临床试验的预先计划的二次分析。
JAMA Oncol. 2020 Sep 1;6(9):1410-1415. doi: 10.1001/jamaoncol.2020.2295.
9
Will traditional biopsy be substituted by radiomics and liquid biopsy for breast cancer diagnosis and characterisation?传统的活检会被放射组学和液体活检取代，用于乳腺癌的诊断和特征分析吗？
Med Oncol. 2020 Mar 16;37(4):29. doi: 10.1007/s12032-020-01353-1.
10
Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.通过循环肿瘤 DNA 基因组分析监测乳腺癌患者的治疗效果和耐药性。
Mol Genet Genomic Med. 2020 Feb;8(2):e1079. doi: 10.1002/mgg3.1079. Epub 2019 Dec 23.
Zotero 插件